Primary Percutaneous Coronary Intervention and Application of the Pharmacoinvasive Approach Within ST-Elevation Myocardial Infarction Care Networks

Can J Cardiol. 2022 Oct;38(10 Suppl1):S5-S16. doi: 10.1016/j.cjca.2021.02.023. Epub 2021 Apr 8.

Abstract

The management of acute ST-elevation myocardial infarction (STEMI) has transitioned from observation and reactive treatment of hemodynamic and arrhythmic complications to accelerated reperfusion and application of evidence-based treatment to minimize morbidity and mortality. International research established the importance of timely reperfusion therapy and the application of fibrinolysis, primary percutaneous coronary intervention (PCI), and subsequent development of the pharmacoinvasive approach. Clinician thought leaders developed and investigated comprehensive systems of care to optimize the outcomes of patients with STEMI, with a key focus in Canada being the integration of prehospital paramedics in diagnosis, triage, and treatment. This article will review highlights of these interventions and identify future challenges and opportunities in STEMI patient care.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / therapy
  • Thrombolytic Therapy
  • Treatment Outcome

Substances

  • Fibrinolytic Agents